explore -WSS

explore

author：knowledge 2025-09-30 00:01:03 - browse：291

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Bird flu makes raw milk dangerous to consume, mouse study finds

knowledge

focus

WSS

The Bio Revolution is changing business and society

Continuity nursing helped my family in our darkest PICU moments

FDA approval of Sarepta Duchenne genetic therapy gives me hope

23andMe had bad news about my health. I wish a person had delivered it

Activists slam private health insurers over coverage restrictions

Sports medicine is finally prioritizing gender equality

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare details structure of new drug price negotiation program

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

As demand for Covid shots wanes, Moderna seeks its next success

Ozempic cut risk of death in diabetes patients with chronic kidney disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Achieving telehealth equity for people with hearing loss

After affirmative action ruling, medical educators look to 'holistic review'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medical leaders decry Supreme Court decision on affirmative action

Decentralized clinical trials need collaboration to achieve wider use

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Duchenne breakthrough therapy leaves behind pioneering families

BioMarin wins approval for gene therapy to treat hemophilia A

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Decentralized clinical trials need collaboration to achieve wider use

Guardant Health colon cancer test endorsed by FDA advisory panel

knowledge

knowledge

focus

hotspot